美国医药专利中非显而易见性审查标准的适用及启示  

Application and Enlightenment of Non-obviousness Standards in the US Pharmaceutical Patents

作　　者：杨秦[1] 师晓荣[1] 刘艳芳[1] 刘会英[1] 赵良[1] 孙海燕[1] 

机构地区：[1]国家知识产权局专利局专利审查协作北京中心

出　　处：《中国发明与专利》2017年第7期113-118,共6页China Invention & Patent

摘　　要：本文梳理了美国专利制度中非显而易见性标准的演变情况,对KSR案前后美国联邦巡回上诉法院判决的几个影响较大的医药专利的非显而易见性判断进行了分析总结,从中可以看出,美国专利非显而易见性经历了从无到有、逐渐趋严的过程,美国法院在对非显而易见性问题上考虑角度全面,标准细化,综合考虑科技发展状况和目前科研水平合理判断等特点可以为我国医药领域专利创造性的把握提供一些启示和借鉴。This article reviews the evolution of non-obviousness in the US patent system, and some important pharmaceutical patent cases from the Court of Appeals for the Federal Circuit before and after KSR case were analyzed. As it can be seen, the non-obviousness of US patent experienced a gradually strict process, the comprehensive consideration, refined standard, appropriate judgment about non-obviousness of the US court can provide some enlightenment to the patent examination about the inventive steps in our country.

关 键 词：美国 医药 专利 非显而易见性 审查 

分 类 号：TQ460.4[化学工程—制药化工]